Liu Y, et al. - In patients with metastatic renal cell carcinoma (mRCC), researchers evaluated the predictive value of tyrosine kinase inhibitors (TKIs)-induced hypertension. The research included a total of 4661 patients from 22 studies. The results of this systematic review and meta-analysis indicate that blood pressure increases were an efficient predictor for longer mRCC patients' progression-free survival (PFS) and overall survival (OS). Subgroup analysis indicated that PFS and OS could be longer for patients receiving sunitinib and pazopanib. This research stated that hypertension induced by TKIs may be a good predictor for better prognosis of mRCC patients receiving therapy with TKIs, particularly with sunitinib or pazopanib.